NEW YORK (GenomeWeb News) – Translational life science tools and molecular diagnostics company NanoString Technologies today filed for an initial public offering.

In its Form S-1 filed with the US Securities and Exchange Commission, the Seattle-based company said it anticipates a proposed maximum aggregate offering price of about $86.3 million, but did not provide a price range for its shares or the amount of shares to be sold.

JP Morgan and Morgan Stanley will be joint book-running managers for the offering, and Leerink Swann and R.W. Baird will act as co-managers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.